Fate Therapeutics Inc. (FATE) Trading Down 2.3%
Fate Therapeutics Inc. (NASDAQ:FATE) traded down 2.3% on Wednesday . The company traded as low as $2.51 and last traded at $2.60, with a volume of 73,667 shares trading hands. The stock had previously closed at $2.66.
A number of equities research analysts recently weighed in on the company. BMO Capital Markets set a $4.00 price target on Fate Therapeutics and gave the company a “buy” rating in a report on Monday, August 8th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Fate Therapeutics in a report on Tuesday, May 10th. Zacks Investment Research raised Fate Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a report on Thursday, August 11th. Leerink Swann reaffirmed an “outperform” rating and set a $4.00 price target on shares of Fate Therapeutics in a report on Tuesday, June 21st. Finally, HC Wainwright assumed coverage on Fate Therapeutics in a report on Thursday, July 28th. They set a “buy” rating and a $9.00 price target for the company. Eight equities research analysts have rated the stock with a buy rating, Fate Therapeutics currently has an average rating of “Buy” and a consensus price target of $6.29.
The company’s 50-day moving average price is $2.26 and its 200 day moving average price is $1.92. The stock’s market cap is $75.12 million.
Fate Therapeutics (NASDAQ:FATE) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.03. The company had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.02 million. Equities research analysts predict that Fate Therapeutics Inc. will post ($1.12) earnings per share for the current fiscal year.
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.